IL-6 Antibody [F4K18] | Primary Antibodies

Application: Reactivity: Mouse

Usage Information

Dilution
WB1:1000 IP1:100 IF1:200 - 1:400 FCM1:400

Application
WB, IP, IF, FCM

Reactivity
Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
24 kDa

Positive Control	Raw 264.7 cells (LPS, 100 ng/ml, 6 h)
Negative Control	Raw 264.7 cells

Datasheet & SDS

Biological Description

Specificity
IL-6 Antibody [F4K18] detects endogenous levels of total IL-6 protein.

Clone
F4K18

Synonym(s)
Interleukin-6; IL-6; B-cell stimulatory factor 2 (BSF-2); CTL differentiation factor (CDF); Hybridoma growth factor; Interferon beta-2 (IFN-beta-2); IL6; IFNB2

Background
Interleukin-6 (IL-6), a pleiotropic glycoprotein cytokine with a four-helix bundle structure and a conserved disulfide bond between Cys44 and Cys50, serves as a central mediator of acute phase responses and immune regulation by binding its α-receptor (IL-6R) to form a high-affinity complex with gp130, which then triggers JAK1/JAK2-mediated tyrosine phosphorylation of gp130 and recruits STAT3 (Tyr705) for nuclear translocation and transcriptional activation of target genes. IL-6 possesses site I/II/III interfaces where key residues such as Phe171, Arg167, and Pro33 mediate receptor docking, with classic signaling via membrane-bound IL-6R driving anti-inflammatory and hepatocyte effects (such as C-reactive protein and fibrinogen induction), while trans-signaling through soluble IL-6R promotes pro-inflammatory responses via activation of MAPK/ERK, PI3K/Akt, and SHP2 pathways. IL-6 stimulates hepatic acute phase protein synthesis, drives B-cell differentiation into plasma cells with IgM and IgG production, induces Th17 polarization while inhibiting Treg differentiation, and coordinates monocyte-to-macrophage transition during infection and injury. IL-6 balances innate and adaptive immunity as well as hematopoiesis, while pathologically, chronic elevation leads to rheumatoid arthritis with synovial inflammation and joint destruction via RANKL-mediated osteoclastogenesis, supports plasma cell survival and proliferation in multiple myeloma, and contributes to cancer cachexia through STAT3-mediated metabolic reprogramming.

Background

Interleukin-6 (IL-6), a pleiotropic glycoprotein cytokine with a four-helix bundle structure and a conserved disulfide bond between Cys44 and Cys50, serves as a central mediator of acute phase responses and immune regulation by binding its α-receptor (IL-6R) to form a high-affinity complex with gp130, which then triggers JAK1/JAK2-mediated tyrosine phosphorylation of gp130 and recruits STAT3 (Tyr705) for nuclear translocation and transcriptional activation of target genes. IL-6 possesses site I/II/III interfaces where key residues such as Phe171, Arg167, and Pro33 mediate receptor docking, with classic signaling via membrane-bound IL-6R driving anti-inflammatory and hepatocyte effects (such as C-reactive protein and fibrinogen induction), while trans-signaling through soluble IL-6R promotes pro-inflammatory responses via activation of MAPK/ERK, PI3K/Akt, and SHP2 pathways. IL-6 stimulates hepatic acute phase protein synthesis, drives B-cell differentiation into plasma cells with IgM and IgG production, induces Th17 polarization while inhibiting Treg differentiation, and coordinates monocyte-to-macrophage transition during infection and injury. IL-6 balances innate and adaptive immunity as well as hematopoiesis, while pathologically, chronic elevation leads to rheumatoid arthritis with synovial inflammation and joint destruction via RANKL-mediated osteoclastogenesis, supports plasma cell survival and proliferation in multiple myeloma, and contributes to cancer cachexia through STAT3-mediated metabolic reprogramming.

References
https://pubmed.ncbi.nlm.nih.gov/32864098/ https://pubmed.ncbi.nlm.nih.gov/32765502/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%